Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Rapid Tests for Chagas Disease Improves Diagnostic Access

By LabMedica International staff writers
Posted on 08 Jul 2025

Chagas disease, caused by the parasite Trypanosoma cruzi, affects between six and seven million people across the Americas. More...

It is primarily transmitted by insect vectors and remains largely underdiagnosed, with less than 1% of those infected receiving treatment. The disease is most commonly diagnosed through serological techniques, which detect antibodies to T. cruzi in the blood during the chronic phase of the disease. However, these methods require specialized personnel and equipment, which are often unavailable in resource-limited areas, making it difficult for people in endemic regions to access proper diagnosis and care. A new approach, combining rapid diagnostic tests (RDTs) with conventional serological techniques, has been proposed to improve access to diagnosis in such settings.

Researchers at the Barcelona Institute for Global Health (ISGlobal, Barcelona, Spain), in collaboration with Paraguayan health authorities, conducted a study involving a screening campaign in an indigenous community in the Paraguayan Chaco, where 999 people were tested. The researchers evaluated the effectiveness of using RDTs for initial screening, followed by confirmation with conventional serological tests such as recombinant and lysate ELISA. The combination of these two methods was found to be highly effective, providing an accessible and rapid solution for diagnosing Chagas disease in remote areas.

The study, published in PLOS Neglected Tropical Diseases, demonstrated that the algorithm using RDTs showed high agreement with the standard algorithm, with a sensitivity of 94.6% and a specificity of 98.6%. The algorithm validated in the study suggests using RDTs for an initial screening of at-risk individuals in endemic areas, thereby reducing the need for serological testing to confirm positive results. The prevalence of the disease was found to be significantly higher in the indigenous community of Casanillo compared to the capital, Asunción, highlighting the health inequalities in urban and rural areas. The researchers plan to further evaluate this approach in other regions and adapt it for broader use in endemic areas to improve access to diagnosis and treatment.

“The results obtained are particularly relevant in the context of a global re-evaluation of guidelines for the diagnosis and treatment of Chagas disease,” said Irene Losada, coordinator of the Chagas Initiative at ISGlobal and senior author of the study. “The adoption of RDT-based algorithms adapted to each region could improve access to diagnosis for thousands of people in remote areas.”

Related Links:
ISGlobal


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.